title: Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review.
authors.affiliation: Marie Curie Palliative Care Research Unit, Department of Mental Health Sciences, Royal Free and University College Medical School, London, UK. b.candy@medsch.ucl.ac.uk
authors.forename: Bridget
authors.initials: B
authors.lastname: Candy
authors.forename: Louise
authors.initials: L
authors.lastname: Jones
authors.forename: Rachael
authors.initials: R
authors.lastname: Williams
authors.forename: Adrian
authors.initials: A
authors.lastname: Tookman
authors.forename: Michael
authors.initials: M
authors.lastname: King
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D006801:Humans; D018783:Impotence, Vasculogenic / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011468:Prostatectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D010726:Phosphodiesterase Inhibitors